NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the lim…
| Métrica | NCNA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | -120.7% | -39.2% | -81.5% |
| ROA | -98.4% | -30.9% | -67.4% |
| Current Ratio | 5.60 | 2.73 | +2.87 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -98.4% | — |
| ✗Flujo de caja operativo positivo | −£7M | −£19M |
| ✓Rentabilidad sobre activos al alza | -98.4% | -128.6% |
| ✓Caja operativa/activos supera al ROA | -25.0% | ROA -98.4% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 5.60 | 1.42 |
| ✗Sin aumentar el nº de acciones | 11,232M | 74M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -80.3% |
NuCana plc cotiza a 0.99 USD y tiene una capitalización bursátil de $4M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud